The Supreme Court has unanimously rejected a challenge from anti-abortion groups to the nationwide availability of the abortion medication mifepristone, which is available by mail and can be taken at home in many states. However, advocates warn the far-right-dominated court’s ruling on the FDA’s authority to regulate the pill was purely on procedural grounds, and could even offer a “roadmap” for future challenges. Mifepristone is used in roughly two-thirds of all U.S. abortions, including in some states that have severely limited or banned abortions. “This is just one of the strikes — not the first strike, not the second or third, but one of the strikes — in an artillery that is aimed at reproductive freedom,” says our guest, legal scholar Michele Goodwin. We discuss the ruling and the anti-abortion movement’s “playbook” of attacks on reproductive healthcare with Goodwin.
This content originally appeared on Democracy Now! and was authored by Democracy Now!.